Technologies
This technology describes a mechanistic pathway of immunosuppression that contributes to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) that could serve as a biomarker or potential therapeutic target.
ME/CFS is a debilitating and heterogenous condition, which is poorly understood with no biomarkers to characterize disease phenotypes or analyze treatment efficacy. There are currently no well-defined relationships between immunologic, metabolic, or gastrointestinal dysfunction and clinical presentation. As such, there are no pharmacological therapeutics specifically geared for symptomatic relief.
This technology identifies a defect in the immune response of patients with ME/CFS linked to enteropathy, compromised intestinal barrier function, and specific metabolic defects. As such, the identified immunosuppression may be remedied with specific metabolic or immunoregulatory alterations, providing a pharmacological therapy. Disease states may also be diagnosed and monitored for response to treatment with the specific immune response defect as a biomarker.
This technology has been validated by data from human subjects at rest and in an exercise challenge.
IR CU22395
Licensing Contact: Jerry Kokoshka